$RIGL News

Last published 1d ago

1d agoRIGLRigel to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...
6d agoRIGLRIGEL PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoRIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial ResultsPR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November
3w agoRIGLRigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswirePooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumorsAdditional analyses highlight first-line clinical outcomes and patient-reported quality of
1mo agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
2mo agoRIGLRigel to Participate in Upcoming September Investor ConferencesPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
3mo agoRIGLRigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast CancerPR NewswireVEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBCSOUTH SAN FRANCISCO, Calif., Aug. 11, 2026
3mo agoRIGLRigel Reports Second Quarter 2026 Financial ResultsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
3mo agoRIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial ResultsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on...
4mo agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
4mo agoRIGLRigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical OfficerPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the ...
4mo agoRIGLRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)PR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the ...
5mo agoRIGLJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - RIGEL PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone, and welcome to the Jeffries Global Healthcare Investment Banking Conference. My name is Tosh Kapadia, and I'm with the Jefferies Investment Bankings team, and it is my great pleasure to introduce
5mo agoRIGLRigel to Present at the Jefferies Global Healthcare ConferencePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
5mo agoRIGLRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the ...
6mo agoRIGLRigel to Present at the 2026 RBC Capital Markets Global Healthcare ConferencePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
6mo agoRIGLRigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast CancerPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
6mo agoRIGLRigel Reports First Quarter 2026 Financial ResultsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
6mo agoRIGLRigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial ResultsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close on...
7mo agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
7mo agoRIGLRigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical OncologyPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
8mo agoRIGLRigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
8mo agoRIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market...
9mo agoRIGLRigel Appoints Michael P. Miller to the Board of DirectorsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more...
10mo agoRIGLRigel Provides Business Update and 2026 OutlookPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a...
10mo agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
10mo agoRIGLRigel to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
11mo agoRIGLRigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and ExpositionPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
11mo agoRIGLRigel to Present at the Piper Sandler 37th Annual Healthcare ConferencePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
11mo agoRIGLRigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a...
12mo agoRIGLRigel to Present at the Jefferies Global Healthcare Conference in LondonPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
1y agoRIGLRigel Reports Third Quarter 2025 Financial Results and Provides Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
1y agoRIGLRigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and ExpositionPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
1y agoRIGL LLYThis biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'CNBCRigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.
1y agoRIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on...
1y agoRIGLRigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDSPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the ...
1y agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
1y agoRIGLRigel to Participate in Upcoming September Investor ConferencesPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
1y agoRIGLRigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoRIGLRigel Reports Second Quarter 2025 Financial Results and Provides Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
1y agoRIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on...
1y agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
1y agoRIGLRigel to Present at the Jefferies Global Healthcare ConferencePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
1y agoRIGLRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced...
1y agoRIGLRigel Reports First Quarter 2025 Financial Results and Provides Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...
1y agoRIGLRigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on...
1y agoRIGLRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireRigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
1y agoRIGLRigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent LitigationPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero...
1y agoRIGLRigel Appoints Mark W. Frohlich, M.D. to Board of DirectorsPR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a...
1y agoRIGLRigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatePR NewswireRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported...